Liquidia Corp (LQDA)

• Market cap: $1.17B
• 1 day: -4.48%
• 5 days: -7.73%
• 1 month: -14.19%
• 3 months: 26.83%
• 6 months: 41.33%
• Year to date: 14.46%
• 1 year: -5.97%
• 5 years: 246.25%
• 10 years: 24.77%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Employees: 145

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

79% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 38

63% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 19

24% more call options, than puts

Call options by funds: $17.1M | Put options by funds: $13.8M

18% more capital invested

Capital invested by funds: $528M [Q3] → $625M (+$96.2M) [Q4]

6% more funds holding

Funds holding: 154 [Q3] → 163 (+9) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 7 [Q3] → 7 (+0) [Q4]

2.72% less ownership

Funds ownership: 63.46% [Q3] → 60.74% (-2.72%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $19 37% upside
• Avg. target: $19 37% upside
• High target: $19 37% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Needham Serge Belanger 48% 1-year accuracy 59 / 123 met price target

37% upside $19

Buy Reiterated

9 Jan 2025